Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (27)

2024

  1. Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

    Pharmaceutics, Vol. 16, Núm. 8

2023

  1. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

    Frontiers in Public Health, Vol. 11

2022

  1. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 6, pp. 941-953

  2. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 236

  3. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925

  4. Insights into the Pharmacokinetics and In Vitro Cell‐Based Studies of the Imidazoline I2 Receptor Ligand B06

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  5. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

    Acta Dermato-Venereologica, Vol. 102

2021

  1. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 222

  2. Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

    Infectious Diseases and Therapy, Vol. 10, Núm. 1, pp. 347-362

  3. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects

    European Journal of Medicinal Chemistry, Vol. 225

  4. Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas

    Biomedicine and Pharmacotherapy, Vol. 140

2020

  1. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 63, Núm. 7, pp. 3610-3633

  2. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6

    Journal of Medicinal Chemistry, Vol. 63, Núm. 17, pp. 9360-9390

  3. Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008-18

    JAC-Antimicrobial Resistance, Vol. 2, Núm. 4

  4. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease

    Neurotherapeutics, Vol. 17, Núm. 4, pp. 1825-1835

  5. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M

    Biomedicine and Pharmacotherapy, Vol. 121

2016

  1. Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013

    Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144

  2. Immune reconstitution inflammatory syndrome in an HIV-infected patient using subcutaneous silicone fillers

    AIDS, Vol. 30, Núm. 16, pp. 2561-2563

2013

  1. BMP2/BMP4 colorectal cancer susceptibility loci in northern and southern european populations

    Carcinogenesis, Vol. 34, Núm. 2, pp. 314-318

  2. Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Pharmacogenomics Journal, Vol. 13, Núm. 3, pp. 209-217